This article is more than 5 years old. Information may no longer be current.

VIDEO: Speaker offers updates in cutaneous squamous cell carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Axel Hauschild, MD, professor of dermatology and head of dermato-oncology at University Hospital in Kiel, Germany, provided an update on treatment of cutaneous squamous cell carcinoma during HemOnc Today Melanoma and Cutaneous Malignancies.

“Cutaneous squamous cell carcinoma is the second most frequent nonmelanoma skin cancer,” Hauschild said. “Ninety percent of these cases have an excellent prognosis because they carry good prognostic factors.”

The treatment of choice among physicians tends to be surgical excision. However, alternatives for inoperable and metastatic disease include radiotherapy, chemotherapy and EGFR inhibitors.

Reference:

Hauschild A. Update on advanced squamous cell carcinomas. Presented at: HemOnc Today Melanoma and Cutaneous Malignancies; March 24-25, 2017; New York.

Disclosure: Hauschild reports consultant or speakers roles with Amgen, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme, Novartis, OncoSec, Philogen, Peirre Fabre, Provectus, Regeneron and Roche.